demonstrated that, after ICI treatment, tumor antigen‐specific CD4+ T cell responses are either induced or enhanced in the peripheral blood of patients with advanced melanoma, with a dominant Th1 immune profile observed.[136] Spitzer et al. The gene discussed is CD4; the disease is melanoma.